Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 22, 2025, at 14:30 [1] - The meeting will include both on-site voting and online voting options [2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on the same day [2] Voting Procedures - Shareholders can attend the meeting in person or authorize a representative to attend [2] - Voting rights can be exercised either through on-site or online voting, but not both for the same proposal [2][3] - The voting results will be based on the first valid vote in case of duplicate voting [2][3] Agenda Items - The meeting will discuss several proposals, including the "2025 Restricted Stock Incentive Plan (Draft)" and its management measures [3] - These proposals require a two-thirds majority approval from the attending shareholders [3][4] Registration Details - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [4][5] - Registration can also be done via mail or fax for remote shareholders, but must be completed by July 21, 2025 [5] Contact Information - For inquiries, shareholders can contact the company via phone, fax, or email [5][6]

Core Viewpoint - The company has announced the completion of the fourth unlock period for its 2021 restricted stock incentive plan, allowing 133,680 shares to be listed for trading, which represents 0.0577% of the total share capital [1][12][21] Group 1: Incentive Plan Details - The company held board meetings to approve the conditions for the fourth unlock period of the 2021 restricted stock incentive plan [2][10] - The total number of shares granted under the incentive plan was adjusted to 10,085,000 shares for 287 incentive targets, with the grant price adjusted from 16.94 yuan to 16.44 yuan per share [4][5] - The fourth unlock period's conditions were partially met, allowing for the release of shares for eligible incentive targets [10][17] Group 2: Unlock Conditions and Performance Metrics - The unlock conditions included no negative audit opinions on the financial reports and no violations of profit distribution regulations [12][13] - The performance target for the unlock period was set at a minimum revenue of 40.3 billion yuan for 2024, with a corresponding unlock ratio based on actual performance [16][17] Group 3: Share Buyback and Cancellation - The company has conducted buybacks and cancellations of restricted stocks for departed employees, totaling 1,877,000 shares across various meetings [6][19][20] - The buyback price for the canceled shares was set at 16.44 yuan per share [6][20] Group 4: Share Structure Changes - Following the unlock, the total share capital remains at 2,318,051,016 shares, with no changes in the overall share structure [21]

Core Points - The company plans to repurchase and cancel 175,000 restricted shares due to 10 incentive recipients not meeting the 100% release conditions from the 2023 incentive plan [1][2] - The decision was approved during the board and supervisory meetings held on April 28, 2025 [1][2] - The repurchase is in accordance with the relevant laws and regulations, including the "Management Measures for Equity Incentives of Listed Companies" [2][5] Repurchase and Cancellation Details - The repurchase involves 10 incentive recipients, with performance evaluations resulting in 4 individuals rated B and 6 rated C, thus not qualifying for full release [2] - The repurchase will be processed through a dedicated securities account at China Securities Depository and Clearing Corporation [2] - The cancellation of shares is expected to be completed by July 8, 2025, followed by necessary business registration changes [3] Share Structure Changes - The share structure will change as follows: - Restricted shares before: 12,630,000; after cancellation: 12,455,000 - Unrestricted shares remain at 1,576,860,735 - Total shares before: 1,589,490,735; after cancellation: 1,589,315,735 [4] Compliance and Legal Opinions - The board confirms that the decision-making process and information disclosure comply with legal requirements and do not harm the rights of incentive recipients or creditors [5] - Legal opinions affirm that the repurchase and cancellation are in line with applicable laws and regulations, ensuring no significant harm to the company or shareholders [5][6]

证券代码：300797 证券简称：钢研纳克 公告编号：2025-033 钢研纳克检测技术股份有限公司 关于首期限制性股票激励计划首次授予部分第二个解除限售期及预留授予部分 第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 其中首次授予部分 97 人， 预留授予部分 10 人。 留授予部分解除限售的限制性股票数量为 247,500 股，占比 0.0647%。 ）于 2025 年 6 月 27 日召开第三届 钢研纳克检测技术股份有限公司（以下简称"公司" 董事会第七次会议、第三届监事会第七次会议，审议通过了《关于首期限制性股票激励计划 首次授予部分第二个解除限售期解除限售条件成就的议案》 《关于制定 <钢研纳克检测技术股份有限公司首期限制性股票激励计划管理办法> 的议案》《关于制定< 钢研纳克检测技术股份有限公司首期限制性股票激励计划实施考核管理办法>的议案》及 《关于提请股东大会授权董事会办理公司首期限制性股票激励计划相关事宜的议案》等议 案。公司独立董事就本次激励计划相关议案发表了独立意见。 同日 ...

Core Viewpoint - The Harbin Senying Window Industry Co., Ltd. has approved the 2025 Restricted Stock Incentive Plan and the list of incentive objects, ensuring compliance with relevant regulations and internal procedures [1][2]. Group 1: Announcement Details - The company held meetings on June 20, 2025, to review and approve the draft of the 2025 Restricted Stock Incentive Plan [1]. - The plan and its summary were disclosed on June 23, 2025, on the company's official information platform [1]. Group 2: Public Disclosure and Verification - The list of incentive objects was publicly disclosed on the company's internal website from June 23 to July 2, 2025, allowing employees to provide feedback [2]. - The Supervisory Board received no objections regarding the incentive object list during the public disclosure period [2]. Group 3: Supervisory Board's Verification Opinion - The Supervisory Board verified that the incentive objects met the conditions set forth in relevant laws and regulations, confirming their eligibility for the incentive plan [3]. - The verification included checks against criteria such as recent disqualifications by the stock exchange or regulatory bodies, ensuring all listed individuals were appropriate candidates [3].

Group 1: Marketing Reform and Sales Strategy - The company is implementing a marketing model reform aimed at optimizing sales models, increasing profit contribution rates, and reducing sales expense ratios. Since 2022, the reform has been piloted in 9 provinces, resulting in steady sales profit growth in these regions. The reform has now been completed in 15 provinces, positively impacting future sales efficiency and profitability [1]. - The new marketing model shifts from solely assessing growth rates to incorporating metrics like per capita efficiency and store efficiency, motivating sales personnel. Future plans include introducing equity incentive programs to align employee benefits with company growth, transitioning personal income from property-based to asset-based income [1]. Group 2: Product Development and Clinical Trials - The Huanglian Jiedu Wan project, China's first "general" syndrome-type traditional Chinese medicine new drug, has completed Phase II and III clinical trials involving 840 cases. The trials focus on validating the drug's effectiveness and safety for treating specific Western medical diseases, providing a basis for future market approval [2]. - The company is progressing with the clinical research of Tang Ning Tong Luo, with patient enrollment ongoing. Updates will be disclosed as the project achieves milestones [2]. Group 3: Competitive Strategy and Market Positioning - The company has defined its new strategic positioning around four platforms: a large-scale manufacturing platform, an industry chain integration platform, an all-channel sales platform, and a large product R&D platform. The manufacturing capacity is expected to increase from 25,000 tons to 60,000 tons annually, enhancing future sales capabilities [3]. - The integration platform aims to strengthen product lines through licensing and branding strategies, while the all-channel sales platform focuses on comprehensive market coverage, including online and offline channels [3]. - The company aims to become a leader in the traditional Chinese medicine sector by leveraging its advantages in production capacity, sales, and R&D to effectively compete in the market [3]. Group 4: Financial Performance and Future Outlook - In Q1 2025, the company experienced a decline in performance due to last year's rapid growth and insufficient market demand. The company plans to focus on its core business and seek new growth points while enhancing its core capabilities and adapting to market changes [4]. - The company emphasizes improving operational quality, cash flow, profitability, and asset return rates through optimized management, sales models, and incentive mechanisms to achieve its annual business goals [4].

Group 1 - The Indian Ministry of Defense is initiating a comprehensive military procurement review to identify Chinese components in military equipment and assess vulnerabilities in the defense supply chain [1] - The Indian Army aims to eliminate Chinese components from its suppliers, emphasizing the reduction of foreign dependency, particularly on China, as a key priority for addressing potential security risks [1] - Recent investigations revealed that some suppliers may have exaggerated the number of domestic components, with critical parts often traceable to China, especially in sensitive areas like drones and anti-drone systems [1] Group 2 - As part of a comprehensive reform plan for 2025, the Indian Ministry of Defense may appoint an external agency to verify domestic production rates, map supply chain dependencies, and evaluate cost structures and technology transfer processes [3] - Following the discovery of Chinese components in military equipment, the Indian Ministry of Defense canceled a drone procurement order citing national security risks, indicating that more defense hardware may require strict inspections to ensure compliance with safety standards [3] - The Ministry of Defense has accelerated procurement processes and intensified scrutiny of suppliers potentially using Chinese components in frontline equipment amid rising tensions with Pakistan [3] Group 3 - The Indian government has decided to terminate a $23 billion Production-Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing, which was intended to increase manufacturing's share in the economy to 25% by 2025 [4] - The PLI scheme, launched four years ago, had around 750 companies, including major players like Foxconn and Reliance Industries, signing up, but many failed to start production or faced slow subsidy payments [5] - As of October 2024, participating companies produced goods worth $151.93 billion under the PLI scheme, achieving only 37% of the set target, with the government disbursing just $1.73 billion in incentives, less than 8% of the allocated funds [5]

Compliance Requirements - The financial accounting report for the most recent accounting year has not received a negative opinion or inability to express an opinion from the registered accountant [3] - Internal controls for the most recent accounting year have not received a negative opinion or inability to express an opinion from the registered accountant [3] - There have been no instances of profit distribution not complying with laws, regulations, company articles, or public commitments in the last 36 months since listing [3] Incentive Object Compliance - The incentive plan does not include shareholders or actual controllers holding more than 5% of the company's shares or their immediate family members [4] - No significant violations leading to administrative penalties or market bans by the China Securities Regulatory Commission (CSRC) in the last 12 months [4] Incentive Plan Compliance - The total number of shares involved in all effective stock incentive plans does not exceed 10% of the company's total share capital [5] - The cumulative shares granted to a single incentive object through all effective stock incentive plans do not exceed 1% of the company's total share capital [5] - The plan includes performance assessment indicators as conditions for the incentive objects to exercise their rights [5] Disclosure Completeness - The plan's purpose, basis for determining incentive objects, and the range of those objects are clearly stated [6] - The number of rights to be granted, types of stocks involved, and their proportion to the company's total share capital are disclosed [6] - The plan's effective period, grant date, and exercise arrangements are specified [6] Independent Financial Advisor - An independent financial advisor has been engaged to verify the feasibility of the incentive plan and its benefits for the company's sustainable development [5] - The advisor's report includes opinions on pricing basis and methods, ensuring no harm to the company's interests or shareholder benefits [5] Performance Assessment Indicators - The performance assessment indicators are objective, public, clear, and beneficial for enhancing the company's competitiveness [6] - At least three comparable companies are selected for benchmarking the indicators [6] Legal Compliance - The company has complied with the conditions for implementing stock incentives as per the relevant regulations [8] - The content of the incentive plan adheres to the provisions of the stock incentive management measures [8] - The procedures for drafting, reviewing, and publicizing the incentive plan comply with the management measures [8]

本公司及监事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688018 证券简称：乐鑫科技 公告编号：2025-048 乐鑫信息科技（上海）股份有限公司 第三届监事会第六次会议决议公告 （一）审议通过《关于调整 2021 年、2022 年、2023 年第二期、2023 年第 三期、2024 年、2025 年限制性股票激励计划授予价格及授予/归属数量的议案》 公司于 2025 年 3 月 22 日及 2025 年 5 月 21 日分别披露了《2024 年年度利 一、监事会会议召开情况 乐鑫信息科技（上海）股份有限公司（以下简称"乐鑫科技"或"公司"）第 三届监事会第六次会议（以下简称"本次会议"）于 2025 年 7 月 2 日在公司 304 会议室以现场方式召开。本次会议的通知于 2025 年 6 月 27 日通过电话及邮件方 式送达全体监事。会议应出席监事 3 人，实际到会监事 3 人，会议由监事会主席 张涵睿主持。会议的召集和召开程序符合有关法律、行政法规、部门规章、规范 性文件和公司章程的规定，会议决议合法、有效。 ...

Core Viewpoint - The legal opinion letter from Shanghai Dongfang Huayin Law Firm confirms that the 2025 Restricted Stock Incentive Plan of Granconxi Communication Technology (Shanghai) Co., Ltd. has obtained the necessary approvals and complies with relevant laws and regulations [2][10]. Group 1: Legal Framework and Compliance - The law firm conducted its review based on the Company Law, Securities Law, and other relevant regulations, ensuring that the legal opinion is accurate and complete [2][3]. - The firm has verified the necessary documents and facts related to the incentive plan, ensuring compliance with the applicable legal standards [3][6]. Group 2: Incentive Plan Adjustments - The number of recipients for the incentive plan has been adjusted from 135 to 133 due to two individuals voluntarily giving up their shares [6][7]. - The total number of restricted stocks to be granted remains unchanged, with the shares being redistributed among the remaining recipients based on various factors [7][10]. Group 3: Granting Details - The grant date for the incentive plan is set for July 1, 2025, which is within the required timeframe following the approval by the shareholders [8][10]. - A total of 1,627,596 shares will be granted at a price of 5.81 yuan per share to the 133 recipients [8][10]. Group 4: Disclosure Obligations - The company will fulfill its information disclosure obligations by announcing the board's resolutions and related documents to the Shanghai Stock Exchange and other designated media [10]. - The firm confirms that the company has complied with the disclosure requirements as per the relevant regulations [10].